Kodiak Sciences (NASDAQ:KOD - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Kodiak Sciences to post earnings of ($0.87) per share for the quarter.
Kodiak Sciences Stock Performance
KOD traded up $0.07 during trading on Friday, reaching $3.28. The company had a trading volume of 563,412 shares, compared to its average volume of 383,489. Kodiak Sciences has a 12-month low of $2.19 and a 12-month high of $11.60. The firm's 50-day simple moving average is $5.32 and its 200 day simple moving average is $5.40. The company has a market cap of $172.61 million, a price-to-earnings ratio of -0.90 and a beta of 2.26.
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group raised Kodiak Sciences from a "hold" rating to a "buy" rating and set a $20.00 target price on the stock in a research note on Monday, December 9th.
Check Out Our Latest Report on Kodiak Sciences
About Kodiak Sciences
(
Get Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Recommended Stories
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
